Ian Haydon on Muck Rack

Ian Haydon

Seattle
As seen in: Medium, Nature, Post Outlook, The Washington Post, CNBC, Fast Company, PNAS, Scientific American, The Conversation, TODAY and
head of comms & AI policy @UWproteindesign 📝📸🎥 // @AAASMassMedia alum // used to study enzymes // he/him

Get in touch with Ian

Contact Ian, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

The past, present and future of de novo protein design

|
By Wei Yang, Shunzhi Wang, Gyu Rie Lee, Jason Zhang, Alexis Courbet, David C Juergens, Xinru Wang, Thomas Schlichthaerle, Mohamad Abedi, Robert J. Ragotte, Linna An, Indrek Kalvet, Sam Pellock, Ljubica Mihaljevic, Cameron J. Glasscock, Arvind Pillai, Adam Broerman, Nathan M. Ennist, Nora K. McNamara-Bordewick, Ian Haydon, Lance Stewart, Gaurav Bhardwaj, David Baker, Ella Haefner
| Nature
Abstract With deep-learning-powered advances in protein design methods, there is an ongoing paradigm shift in protein engineering from random selection to intentional computational design methods. Here we describe the current state of de novo protein design. While there is still room for improvement in success rates and activities, the long-standing challenges of designing new protein structures, assemblies and protein binders are close to being solved.
Open in Who Shared Issue with article?

Designed protein switches may lead to safer, smarter medicines

|
By Ian Haydon
| EurekAlert!
A new way to potentially control when drugs are active or inactive in the body is introduced in a study reported Sept. 24 in Nature. The research showed that, instead of controlling how tightly proteins bind to partner molecules, scientists can now directly control how long they stay bound. This advance has broad implications for developing safer medicines. “One way to control a medicine is through dose.
Open in Who Shared View Duplicates (3) Issue with article?

Exploring Outsourcing's Role In CGT Scalability And Affordability

|
By Fahimeh Mirakhori, Ian Haydon
| Bioprocess Online
By Fahimeh Mirakhori, M.Sc., Ph.D. Advanced biologics, such as cell and gene therapies (CGTs), administered either ex vivo or in vivo, have shown unprecedented promise in addressing previously untreatable conditions. Yet despite their clinical successes, their global accessibility remains constrained by a complex interplay of scientific, manufacturing, pricing, and policy challenges.
Open in Who Shared Issue with article?
See all 225 articles

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Ian

Contact Ian, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified